

## **PreS 2020 LIGHTENING TALKS & E-POSTERS on SJIA and MAS**

### Lightening Talks

- LONG-TERM SAFETY PROFILE OF ANAKINRA IN PATIENTS WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS – G. Giancane
- EARLY TREATMENT AND IL1RN SNPS AFFECT RESPONSE TO ANAKINRA IN SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS – M. Rossi
- CANAKINUMAB IN SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS: CLINICAL INACTIVE DISEASE RATE AND SAFETY IN ITALIAN PATIENTS – A. De Matteis
- APPLICATION OF SYSTEMS BIOLOGY-BASED IN SILICO TOOLS TO OPTIMIZE TREATMENT STRATEGY IN STILL'S DISEASE – M. Coma
- PAEDIATRIC MULTI-SYSTEM INFLAMMATORY SYNDROME TEMPORALLY ASSOCIATED WITH SARS-COV-2 MIMICKING KAWASAKI DISEASE (KAWA-COVID-19): A MULTICENTRE COHORT – I. Melki
- STUDY OF EMAPALUMAB, A FULLY HUMAN, ANTI-IFN GAMMA MONOCLONAL ANTIBODY, IN PATIENTS WITH MAS/SHLH ON A BACKGROUND OF SJIA AND WITH INADEQUATE RESPONSE TO HIGH-DOSE GLUCOCORTICOIDS – F. De Benedetti
- RISK SCORE OF MACROPHAGE ACTIVATION SYNDROME IN PATIENTS WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS – S. Carbogno
- A PATIENT WITH IFNAR2 DEFICIENCY CAUSING DYSREGULATION OF NK CELL FUNCTIONS AND PRESENTING WITH HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS – G. Prencipe
- TRADITIONAL LABORATORY PARAMETERS AND NEW BIOMARKERS IN MACROPHAGE ACTIVATION SYNDROME (MAS) AND SECONDARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (SHLH) – A. De Matteis
- MACROPHAGE ACTIVATION SYNDROME IN JUVENILE SYSTEMIC LUPUS ERYTHEMATOSUS: A SINGLE CENTER STUDY OF NINETEEN PATIENTS – I. Nikishima
- PEDIATRIC SYSTEMIC MULTI-INFLAMMATORY DISEASES IN ITALY DURING SARS-COV-2 EPIDEMIC: FROM KAWASAKI DISEASE TO KAWACOVID – M. Cattalini
- IMMUNOPATHOGENESIS OF COVID-19-RELATED PEDIATRIC INFLAMMATORY MULTISYSTEM SYNDROME: CYTOKINE PROFILE AND SARS-COV-2 SPECIFIC IMMUNE COMPLEXES – L. Alsina

### E-Posters

- MAS/sJIA WORKING PARTY ACTIVITIES – C. Bracaglia
- THE SHARE RECOMMENDATIONS ON DIAGNOSIS AND TREATMENT OF SYSTEMIC JIA – B. Vastert
- APPLICATION OF PRELIMINARY PRINTO CLASSIFICATION CRITERIA FOR SJIA IN AN INDIAN COHORT – D. Pandya
- CANAKINUMAB AS FIRST- OR SECOND-LINE DMARD IN SYSTEMIC-ONSET JUVENILE IDIOPATHIC ARTHRITIS (SJIA) - DATA FROM THE GERMAN BIKER REGISTRY – R. Heidebrecht
- PATIENT PERSPECTIVES ON LIVING WITH SJIA OR STILL'S DISEASE: IMPACT ON QUALITY OF LIFE – R. Sinha
- SPIDER BITE MIMICKING PYODERMA GANGRENOSUM IN SJIA: A CASE REPORT – MC Maggio
- THE ROLE OF INTRA-ARTICULAR GLUCOCORTICOID INJECTIONS (IAGI) IN SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA): A SINGLE CENTER EXPERIENCE – A. Uva

- COXARTHROSIS RISK FACTORS IN SYSTEMIC AND NON-SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS – L. Sorokina
- EFFECT OF DOSE AND DURATION OF GLUCOCORTICOID TREATMENT ON PROGNOSIS OF SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS – S. Ozdemir Cicek
- IS KAWASAKI DISEASE OR SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS IN CHILDREN WITH FEVER WITHOUT A SOURCE ? – B. Sozeri
- PERFORMANCE OF THE “MS-SCORE” AND “HSCORE” IN THE DIAGNOSIS OF MAS IN SYSTEMIC JIA PATIENTS – E. Sag
- "MACROPHAGE ACTIVATION SYNDROME : 12 YEARS DATA FROM AN INDIAN CENTER" – P.Pal
- AN UNUSUAL CASE OF MACROPHAGE ACTIVATION SYNDROME, COMPLICATED BY THROMBOTIC MICROANGIOPATHY, WITH CLINICAL RESPONSE TO IL-1 BLOCKADE – K. McIllean
- KAWASAKI DISEASE COMPLICATED BY MACROPHAGE ACTIVATION SYNDROME AND PARVOVIRUS B19 INFECTION: WHICH RELATIONSHIP? – G. Martini
- LIFE-THREATENING MACROPHAGE ACTIVATION SYNDROME WITH FULMINANT MYOCARDITIS SUCCESSFULLY RESCUED BY HIGH DOSE INTRAVENOUS ANAKINRA – A. Meneghel
- MACROPHAGE ACTIVATION SYNDROME IS A PREVENTABLE LIFE-THREATENING END POINT SYNDROME – D. Pandya
- OVERLAP SYNDROME OF IDIOPATHIC INFLAMMATORY MYOPATHY WITH JUVENILE SYSTEMIC LUPUS ERYTHEMATOSUS PRESENTING WITH MACROPHAGE ACTIVATION SYNDROME – R. Braganca
- SYSTEMIC JIA, KAWASAKI SYNDROME AND MACROPHAGE ACTIVATION, WHAT ELSE? NOT ONLY COVID-19 – R. Dagher
- HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS IN INFANCY: A CASE SERIES – B. Harikrishnan